Forensic Analysis · Industrials / Manufacturing / Defense · as of Jul 3, 2026
ChronoScale Corp (CHRN)
A forensic read on ChronoScale Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-44.4
Altman Z-score
Clean
Earnings quality
5
Forensic signals
-177.4%
ROE
$2.4B
Market cap
ChronoScale Corp earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -44.4, placing it in the Distress zone. 5 forensic signals were flagged in its latest SEC filings, led by receivables vs revenue.
What the filings flag
208d DSOReceivables vs revenue.Days sales outstanding moved from 147 to 208 days FY2024→FY2025 (receivables +1% vs revenue -29%). Receivables are outrunning sales — a flag for aggressive revenue recognition or slipping collections.
296dInventory days.Days inventory outstanding moved from 198 to 296 FY2024→FY2025 (against cost of goods sold; inventory +5% vs -29% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.
-102%Return on invested capital.Return on invested capital is -102% and rising from -110% — well below its ~9% cost of capital, so reinvested dollars may be destroying value, not building it.
+21.4%/yrShare-count dilution.Diluted share count changed +64% over the last 3 years to FY2024 (+21.4%/yr). A reversal: the count shrank earlier (net -6.2%/yr since FY2017) but the company has SWUNG to issuing stock — recent holders are now being diluted, not rewarded. That's ~21.4% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2021 has been diluted ~64%.
$189,000Goodwill impairments.Took $189,000 of goodwill writedowns across 1 year(s) (FY2020 ($189,000)). Writedowns mean past acquisitions underperformed what was paid for them — worth weighing on capital-allocation skill.
Key fundamentals
Net Margin-91.4%
Debt / Equity0.22x
Free Cash Flow$-12.0M
Latest Revenue$12.8M
Return on Equity-129.6%
Revenue Growth YoY-28.6%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on ChronoScale Corp:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about CHRN's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown